Cytokinetics (CYTK) Revenue (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Revenue of $19.4 million for Q1 2026, up 1125.78% year-over-year from $1.6 million in Q1 2025, and up 9.01% quarter-over-quarter from $17.8 million in Q4 2025.
Cytokinetics (CYTK) Revenue (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Revenue for 17 consecutive years, with $19.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 1125.78% year-over-year to $19.4 million; the TTM figure through Mar 2026 stood at $105.8 million (up 511.97% YoY), while the FY2025 annual figure was $88.0 million, up 486.93% from the prior year.
- Revenue climbed to $19.4 million in Q1 2026 per CYTK's latest filing, from $17.8 million in the prior quarter.
- Across five years, Revenue topped out at $89.0 million in Q2 2022 and bottomed at $249000.0 in Q2 2024.
- Historically, Revenue has averaged $13.3 million across 5 years, with a median of $1.9 million in 2025.
- Annual changes were most pronounced in 2023 — Revenue tumbled 99.03% — and 2025, when it soared 26714.86%.
- Cytokinetics' Revenue stood at $2.0 million in 2022, then dropped by 14.56% to $1.7 million in 2023, then surged by 797.13% to $15.0 million in 2024, then grew by 18.37% to $17.8 million in 2025, then increased by 9.01% to $19.4 million in 2026.
- Business Quant data shows CYTK's Revenue at $19.4 million in Q1 2026, $17.8 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 28.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.62 Mn |
| Mar 31, 2026 | 19.36 Mn |
| Dec 31, 2025 | 17.76 Mn |
| Sep 30, 2025 | 1.94 Mn |
| Jun 30, 2025 | 66.77 Mn |
| Mar 31, 2025 | 1.58 Mn |
| Dec 31, 2024 | 15.00 Mn |
| Sep 30, 2024 | 463,000.00 |
| Jun 30, 2024 | 249,000.00 |
| Mar 31, 2024 | 835,000.00 |
| Dec 31, 2023 | 1.67 Mn |
| Sep 30, 2023 | 378,000.00 |
| Jun 30, 2023 | 867,000.00 |
| Mar 31, 2023 | 4.61 Mn |
| Dec 31, 2022 | 1.96 Mn |
| Sep 30, 2022 | 2.52 Mn |
| Jun 30, 2022 | 88.97 Mn |
| Mar 31, 2022 | 1.15 Mn |
| Dec 31, 2021 | 40.07 Mn |
| Sep 30, 2021 | 5.44 Mn |